Stock Report

Torrent Pharmaceuticals Limited Reports Q1 FY27 Results: Revenue Surges 55% YoY to ₹4,921 Crore; Net Profit Reaches ₹566 Crore

Posted On : 2026-07-31 13:31:09( TIMEZONE : IST )

Torrent Pharmaceuticals Limited, a major Indian multinational pharmaceutical company, has released its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026 (Q1 FY27). The company reported significant top-line expansion, driven by strong performance across its domestic and international operations along with the integration of the JB business.

Consolidated Financial Highlights

All figures in ₹ Crore unless explicitly stated otherwise.

For Q1 FY27, Torrent Pharma reported a consolidated Net Profit After Tax (PAT) of ₹566 crore, representing a 3.28% year-on-year increase compared to ₹548 crore in Q1 FY26 and expanding 55.49% sequentially from ₹364 crore in Q4 FY26.

Total consolidated revenue from operations for the quarter surged 54.85% year-on-year to ₹4,921 crore, up from ₹3,178 crore in Q1 FY26 and ₹4,197 crore in Q4 FY26.

Gross Profit: Reached ₹3,758 crore with a gross margin of 76.4%, up 56% YoY from ₹2,404 crore (75.6% margin) in Q1 FY26.

Operating EBITDA (before exceptional items): Expanded 61% year-on-year to ₹1,664 crore, delivering an Operating EBITDA margin of 33.8% (compared to 32.5% in Q1 FY26).

Expenses Breakup: Total consolidated expenses stood at ₹4,155 crore (vs. ₹2,403 crore in Q1 FY26). Major line items included:

Other Expenses: ₹1,201 crore.

Employee Benefits Expense: ₹893 crore (vs. ₹605 crore in Q1 FY26).

Cost of Materials Consumed: ₹609 crore.

Depreciation & Amortisation Expense: ₹593 crore (vs. ₹201 crore in Q1 FY26).

Purchases of Stock-in-Trade: ₹531 crore.

Finance Costs: ₹305 crore (vs. ₹56 crore in Q1 FY26).

R&D Spend: Stood at ₹172 crore (4% of revenues), compared to ₹157 crore (5% of revenues) in Q1 FY26.

Exceptional Items: The company recorded an exceptional charge of ₹21 crore during Q1 FY27.

Profit Before Tax (PBT): Came in at ₹733 crore for Q1 FY27, compared to ₹738 crore in Q1 FY26 and ₹529 crore in Q4 FY26.

Tax Expense: Totaled ₹167 crore (comprising ₹254 crore current tax and ₹(87) crore deferred tax credit).

Total Comprehensive Income: Stood at ₹645 crore for Q1 FY27 against ₹546 crore in Q1 FY26.

Business Unit & Segment Performance

Consolidated revenues for Q1 FY27 were powered by both the Base Business and the JB Business:

1. Base Business Summary

Base Revenues: ₹3,720 crore, up 17% YoY.

Base Op. EBITDA: ₹1,240 crore (20% YoY growth) with a 33.3% margin.

India (Base): Revenue reached ₹2,157 crore (19% YoY growth vs. IPM growth of 12%). Torrent achieved the #1 rank in the IPM cardiac market and secured a 36% market share in Gx Semaglutide (oral + injectable).

Brazil: Revenue grew 27% YoY to ₹277 crore (R$ 147 million in constant currency, up 3%).

United States: Revenue rose 36% YoY to ₹418 crore ($44 million in constant currency, up 23%).

Germany: Revenue stood at ₹318 crore, up 3% YoY (€29 million in constant currency, down 9% due to third-party supply disruptions).

2. JB Business Summary

JB Revenues: ₹1,201 crore, up 10% YoY.

JB Gross Profit: ₹859 crore (71.5% margin), up 15% YoY.

JB Op. EBITDA: ₹424 crore (35.3% margin), up 34% YoY.

India Rx (ex-generics + contrast media): ₹657 crore, up 13% YoY.

International (US + Emerging Markets + CDMO): ₹468 crore, up 12% YoY (CDMO revenue grew 27% to ₹145 crore).

Consolidated Regional Revenue Breakdown

India: Base ₹2,157 cr | JB ₹733 cr | Total: ₹2,890 cr (+60% YoY overall, +19% Base)

International: Base ₹1,451 cr | JB ₹468 cr | Total: ₹1,919 cr (+57% YoY overall, +19% Base)

Others: Base ₹112 cr | Total: ₹112 cr (-24% YoY)

Total Revenues: ₹4,921 cr (+55% YoY overall, +17% Base)

Standalone Performance Summary

All figures in ₹ Crore unless explicitly stated otherwise.

On a standalone basis, Torrent Pharmaceuticals reported:

Total Revenue from Operations: Reached ₹4,158 crore in Q1 FY27, up 58.94% YoY compared to ₹2,616 crore in Q1 FY26 and ₹3,445 crore in Q4 FY26.

Total Income: Stood at ₹4,137 crore (reflecting other income of ₹(21) crore).

Total Expenses: Came in at ₹3,453 crore, driven by other expenses of ₹970 crore, employee expenses of ₹677 crore, material costs of ₹609 crore, and depreciation of ₹575 crore.

Profit Before Tax (PBT): Reached ₹663 crore (after ₹21 crore exceptional item), compared to ₹742 crore in Q1 FY26.

Net Profit After Tax (PAT): Came in at ₹492 crore for Q1 FY27, compared to ₹551 crore in Q1 FY26 and ₹309 crore in Q4 FY26.

Total Comprehensive Income: Stood at ₹559 crore for Q1 FY27.

Earnings Per Share & Key Financial Ratios

Consolidated EPS: Basic and diluted Earnings Per Share for Q1 FY27 stood at ₹14.87 per share (face value ₹5.00 each, not annualised), up from ₹11.51 in Q4 FY26.

Standalone EPS: Basic and diluted EPS came in at ₹12.94 per share for Q1 FY27, compared to ₹7.74 in Q4 FY26.

Paid-Up Equity Share Capital: Remained unchanged at ₹169.23 crore (face value ₹5.00 per share).

Debt Equity Ratio: Stood at 0.78 as of June 30, 2026 (vs. 0.81 in March 2026).

Operating Margin: Improved to 37.2% on a standalone basis (vs. 34.6% in Q4 FY26).

Net Profit Margin: Stood at 11.8% on a standalone basis for Q1 FY27.

Shares of Torrent Pharmaceuticals Limited was last trading in BSE at Rs. 4870.65 as compared to the previous close of Rs. 4877.40. The total number of shares traded during the day was 56095 in over 5202 trades.

The stock hit an intraday high of Rs. 4950.50 and intraday low of 4861.25. The net turnover during the day was Rs. 275696833.00.